Drug class
Therapeutic radiopharmaceutical; prostate-specific membrane antigen (PSMA)-targeted radioligand therapy
Mechanism of action
A small-molecule ligand binds with high affinity to PSMA on prostate cancer cells and delivers beta-minus radiation from lutetium-177. The emitted radiation induces DNA damage in targeted and nearby cells, potentially leading to cell death.
General use cases
- Treatment of adults with PSMA-positive metastatic prostate cancer under the applicable product label; patient selection and approved treatment setting depend on prior androgen-receptor pathway therapy and taxane exposure.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
